Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases

Liver Resection Remains a Safe Procedure After Neoadjuvant Chemotherapy Including Bevacizumab

(2010) Dietmar Tamandl et al.   ANNALS OF SURGERY

Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases?

(2010) Rene Adam et al.   ANNALS OF SURGERY

Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: Preliminary results of a case–control study

(2010) P. Pessaux et al.   EJSO

Chemotherapy, Liver Injury, and Postoperative Complications in Colorectal Liver Metastases

(2010) Frank Makowiec et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Impact of Complications After Surgery for Colorectal Liver Metastasis on Patient Survival

(2010) Abbey Schepers et al.   JOURNAL OF SURGICAL RESEARCH

Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial

(2010) Gianluca Masi et al.   LANCET ONCOLOGY

Liver failure after partial hepatic resection: definition, pathophysiology, risk factors and treatment

(2010) Maartje A. J. Van Den Broek et al.   LIVER INTERNATIONAL

Inductive angiocrine signals from sinusoidal endothelium are required for liver regeneration

(2010) Bi-Sen Ding et al.   NATURE

Effect of Postoperative Morbidity on Long-term Survival After Hepatic Resection for Metastatic Colorectal Cancer

(2009) Hiromichi Ito et al.   ANNALS OF SURGERY

Long-Term Outcome of Initially Unresectable Metastatic Colorectal Cancer Patients Treated with 5-Fluorouracil/Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Followed by Radical Surgery of Metastases

(2009) Gianluca Masi et al.   ANNALS OF SURGERY

Trends in Perioperative Outcome After Hepatic Resection

(2009) Matteo Cescon et al.   ANNALS OF SURGERY

Preoperative Liver Hypertrophy Induced by Portal Flow Occlusion Before Major Hepatic Resection for Colorectal Metastases Can Be Impaired by Bevacizumab

(2009) Béatrice Aussilhou et al.   ANNALS OF SURGICAL ONCOLOGY

Outcome after Resection of Hepatic and Pulmonary Metastases of Colorectal Cancer

(2009) Hannes Neeff et al.   JOURNAL OF GASTROINTESTINAL SURGERY

Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer

(2009) Jolien Tol et al.   NEW ENGLAND JOURNAL OF MEDICINE

Anti-Epidermal Growth Factor Receptor Monotherapy in the Treatment of Metastatic Colorectal Cancer: Where Are We Today?

(2009) M. Peeters et al.   ONCOLOGIST

Colorectal Cancer Epidemiology: Incidence, Mortality, Survival, and Risk Factors

(2009) Fatima Haggar et al.   Clinics in Colon and Rectal Surgery

Chemotherapy With Bevacizumab Does Not Affect Liver Regeneration After Portal Vein Embolization in the Treatment of Colorectal Liver Metastases

(2008) Daria Zorzi et al.   ANNALS OF SURGICAL ONCOLOGY

Preoperative Bevacizumab Does Not Significantly Increase Postoperative Complication Rates in Patients Undergoing Hepatic Surgery for Colorectal Cancer Liver Metastases

(2008) Susan B. Kesmodel et al.   JOURNAL OF CLINICAL ONCOLOGY

K-rasMutations and Benefit from Cetuximab in Advanced Colorectal Cancer

(2008) Christos S. Karapetis et al.   NEW ENGLAND JOURNAL OF MEDICINE

Expanding Criteria for Resectability of Colorectal Liver Metastases

(2008) T. M. Pawlik et al.   ONCOLOGIST

Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases

(2007) Srinevas K. Reddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS